Stocksigma LogoStocksigma Logo

Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials

Mankind Pharma approved the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent entity, with an appointed

Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials

Mankind Pharma Ltd · Others (Uncategorized) · 26 Oct 2026, 8:54 pm

Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials Mankind Pharma approved the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent entity, with an appointed date of 1st Apr'27, involving no share issuance or cash consideration. For Q2 ended 30th Sep'26, consolidated revenue from operations grew 17.3% YoY to ₹4,337.86 crore, while consolidated profit after tax rose 37.7% YoY to ₹716.12 crore. Separately, the board noted the merger of step-down subsidiary Upakarma Ayurveda into Mankind Consumer Products to optimize operations and strengthen direct-to-consumer capabilities.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements